CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2017--
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company
pioneering the development of medicines to control the expression of
disease-driving genes, today announced that its Chief Executive Officer
Nancy Simonian, M.D., will present a corporate overview at the 35th
Annual J.P. Morgan Healthcare Conference. Details are as follows:
35th Annual J.P. Morgan Healthcare Conference
Wednesday, January 11
Time: 3 p.m. PT (6 p.m. ET)
Westin St. Francis Hotel, 335 Powell Street., San Francisco, CA
The presentation will be followed by a question and answer session.
A live webcast of the presentation and question and answer session can
be accessed under Events & Presentations in the News and Investors
section of the Company's website at www.syros.com.
A downloadable copy of the corporate slide presentation is also
available on the News and Investors section of the website. A replay of
the webcast will be archived on the website for approximately 30 days
following the presentation.
About Syros Pharmaceuticals
Syros Pharmaceuticals is
pioneering the understanding of the non-coding region of the genome to
advance a new wave of medicines that control expression of
disease-driving genes. Syros has built a proprietary platform that is
designed to systematically and efficiently analyze this unexploited
region of DNA in human disease tissue to identify and drug novel targets
linked to genomically defined patient populations. Because gene
expression is fundamental to the function of all cells, Syros’ gene
control platform has broad potential to create medicines that achieve
profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is
advancing a growing pipeline of gene control medicines. Syros’ lead drug
candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical
trial for genomically defined subsets of patients with acute myeloid
leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7
inhibitor with potential in a range of solid tumors and blood cancers.
Led by a team with deep experience in drug discovery, development and
commercialization, Syros is located in Cambridge, Mass.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170110005978/en/
Source: Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc.
Stern Investor Relations, Inc.